Disposition of [14C] ABT-199 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Following a Single Oral Dose Administration

Trial Profile

Disposition of [14C] ABT-199 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Following a Single Oral Dose Administration

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2014

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Nov 2014 Last checked against ClinicalTrials.gov record.
    • 12 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 09 Jun 2014 Planned initiation date changed from 1 May 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top